Patents Assigned to Civitas Therapeutics, Inc.
-
Patent number: 8747813Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.Type: GrantFiled: March 6, 2013Date of Patent: June 10, 2014Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
-
Publication number: 20140150787Abstract: A device for puncturing a capsule to release a powdered medicament therefrom includes a chamber for receiving the capsule. The capsule includes opposing domes and a cylindrical wall portion defined by a capsule wall radius r. The device further includes a mechanism for puncturing at least one hole in at least one dome. A center of each hole is located within an annular puncture region situated at no less than 0.4 r, and a total surface area of all puncture holes is between about 0.5% and about 2.2% of a total surface area of the capsule. The annular puncture region may, for example, be situated between about 0.4 r and about 0.8 r, or between about 0.4 r and about 0.6 r.Type: ApplicationFiled: December 19, 2012Publication date: June 5, 2014Applicant: Civitas Therapeutics, Inc.Inventors: Colleen Ellwanger, Brian Noble, Tim Coker, Sean Plunkett
-
Publication number: 20140148424Abstract: The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.Type: ApplicationFiled: November 19, 2013Publication date: May 29, 2014Applicant: Civitas Therapeutics, Inc.Inventors: Charles D. Blizzard, Michael M. Lipp, Kevin L. Ward, Rachel Ryznal, Daniel Leblanc, Mark Tracy, Rebecca Martin
-
Publication number: 20140105983Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.Type: ApplicationFiled: October 17, 2013Publication date: April 17, 2014Applicant: Civitas Therapeutics, Inc.Inventors: Blair C. Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
-
Patent number: 8685442Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.Type: GrantFiled: July 18, 2013Date of Patent: April 1, 2014Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Michael M. Lipp, Abhijit Kamerkar, Ernest D. Penachio, Kevin D. Kee
-
Patent number: 8628754Abstract: A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50% of the mass of particles. The particles are capable of carrying agents. The agent is (1) part of the spray-drying pre-mixture and thereby incorporated into the particles, (2) added to separately-prepared particles so that the agent is in chemical association with the particles or (3) blended so that the agent is mixed with, and co-delivered with the particles. Respirable compositions comprising carrier particles having a tap density of less than 0.4 g/cm3 and a composition comprising an agent are also disclosed. Methods of delivering these respirable compositions are also included.Type: GrantFiled: December 22, 2011Date of Patent: January 14, 2014Assignee: Civitas Therapeutics, Inc.Inventors: David A. Edwards, Richard P. Batycky, Lloyd Johnston
-
Publication number: 20140007874Abstract: An improved inhalation device is provided for facilitating inhalation by a patient of powder medicaments contained in a receptacle. The inhalation device includes a staple assembly comprising a plunger and staple that are securely and robustly coupled to one another. Embodiments of the inhalation device have a cap that prevents or reduces the amount of dust and grime entering into the device. The cap is additionally configured to prevent or reduce inadvertent and unintentional operation of the device. The body portion and first casing portion of certain embodiments of the inhalation device are sealably coupled, restricting or reducing undesirable flow pathways that have an adverse effect on the operation of the device.Type: ApplicationFiled: June 28, 2013Publication date: January 9, 2014Applicant: Civitas Therapeutics, Inc.Inventors: Colleen Ellwanger, Brian Noble, Chuck Ganem, Jake Ganem, Kevin Stapleton
-
Patent number: 8614255Abstract: The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.Type: GrantFiled: August 21, 2008Date of Patent: December 24, 2013Assignee: Civitas Therapeutics, Inc.Inventors: Charles D. Blizzard, Michael M. Lipp, Kevin L. Ward, Rachel Ryznal, Daniel Leblanc, Mark Tracy, Rebecca Martin
-
Publication number: 20130306069Abstract: The invention relates to a method of delivering an agent to the pulmonary system of a compromised patient, in a single breath-activated step, comprising administering a particle mass comprising an agent from an inhaler containing less than 5 milligrams of the mass, wherein at least about 50% of the mass in the receptacle is delivered to the pulmonary system of a patient. The invention also relates to receptacles containing the particle mass and the inhaler for use therein.Type: ApplicationFiled: May 2, 2013Publication date: November 21, 2013Applicant: Civitas Therapeutics, Inc.Inventor: Jeffrey S. Hrkach
-
Patent number: 8545878Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.Type: GrantFiled: November 16, 2012Date of Patent: October 1, 2013Assignee: Civitas Therapeutics, Inc.Inventors: Kevin Kee, Ernest D. Penachio, Abhijit Kamerkar, Michael M. Lipp, Richard P. Batycky
-
Publication number: 20130253065Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.Type: ApplicationFiled: March 6, 2013Publication date: September 26, 2013Applicant: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
-
Patent number: 8496002Abstract: An improved inhalation device is provided for facilitating inhalation by a patient of powder medicaments contained in a receptacle. The inhalation device includes a staple assembly comprising a plunger and staple that are securely and robustly coupled to one another. Embodiments of the inhalation device have a cap that prevents or reduces the amount of dust and grime entering into the device. The cap is additionally configured to prevent or reduce inadvertent and unintentional operation of the device. The body portion and first casing portion of certain embodiments of the inhalation device are sealably coupled, restricting or reducing undesirable flow pathways that have an adverse effect on the operation of the device.Type: GrantFiled: June 10, 2008Date of Patent: July 30, 2013Assignee: Civitas Therapeutics, Inc.Inventors: Colleen Ellwanger, Brian Noble, Chuck Ganem, Jake Ganem, Kevin Stapleton
-
Publication number: 20130164349Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.Type: ApplicationFiled: February 21, 2013Publication date: June 27, 2013Applicant: Civitas Therapeutics, Inc.Inventor: Civitas Therapeutics, Inc.
-
Patent number: 8454939Abstract: The invention relates to a method of delivering an agent to the pulmonary system of a compromised patient, in a single breath-activated step, comprising administering a particle mass comprising an agent from an inhaler containing less than 5 milligrams of the mass, wherein at least about 50% of the mass in the receptacle is delivered to the pulmonary system of a patient. The invention also relates to receptacles containing the particle mass and the inhaler for use therein.Type: GrantFiled: April 28, 2011Date of Patent: June 4, 2013Assignee: Civitas Therapeutics, Inc.Inventor: Jeffrey S. Hrkach
-
Patent number: 8415397Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.Type: GrantFiled: April 8, 2011Date of Patent: April 9, 2013Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
-
Patent number: 8404276Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.Type: GrantFiled: December 20, 2010Date of Patent: March 26, 2013Assignee: Civitas Therapeutics, Inc.Inventors: Blair Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
-
Publication number: 20130071440Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.Type: ApplicationFiled: August 17, 2012Publication date: March 21, 2013Applicant: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
-
Patent number: 8268358Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.Type: GrantFiled: January 20, 2011Date of Patent: September 18, 2012Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
-
Publication number: 20120111325Abstract: The invention relates to a method of delivering an agent to the pulmonary system of a compromised patient, in a single breath-activated step, comprising administering a particle mass comprising an agent from an inhaler containing less than 5 milligrams of the mass, wherein at least about 50% of the mass in the receptacle is delivered to the pulmonary system of a patient. The invention also relates to receptacles containing the particle mass and the inhaler for use therein.Type: ApplicationFiled: April 28, 2011Publication date: May 10, 2012Applicant: Civitas Therapeutics, Inc.Inventor: Jeffrey S. Hrkach
-
Patent number: RE43711Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.Type: GrantFiled: October 17, 2011Date of Patent: October 2, 2012Assignee: Civitas Therapeutics, Inc.Inventors: Blair Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich